1. Willemze R, Jaffe ES, Burg G et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768–85.
2. DeCoteau JF, Butmarc JR, Kinney MC, Kadin ME. The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: comparison with anaplastic large-cell lymphoma of nodal origin. Blood 1996; 87: 3437–41.
3. Vergier B, Belaud-Rotureau MA, Benassy MN et al. Neoplastic cells do not carry bcl2-JH rearrangements detected in a subset of primary cutaneous follicle center B-cell lymphomas. Am J Surg Pathol 2004; 28: 748–55.
4. Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization classification of Tumors. Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues. Lion: IARC Press, 2001.
5. Willemze R, Kerl H, Sterry W, Berti E et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 1997; 90: 354–71.
6. Miyamoto T, Yoshino T, Takehisa T et al. Cutaneous presentation of nasal/nasal type T/NK cell lymphoma: clinicopathological findings of four cases. Br J Dermatol 1998; 139: 481–7.
7. El Shabrawi-Caelen L, Cerroni L, Kerl H. The clinicopathologic spectrum of cytotoxic lymphomas of the skin. Semin Cutan Med Surg 2000; 19: 118–23.
8. Natkunam Y, Smoller BR, Zehnder JL et al. Aggressive cutaneous NK and NK-like T-cell lymphomas: clinicopathologic, immunohistochemical, and molecular analyses of 12 cases. Am J Surg Pathol 1999; 23: 571–81.
9. Agnarsson BA, Vonderheid EC, Kadin ME. Cutaneous T cell lymphoma with suppressor/cytotoxic (CD8) phenotype: identification of rapidly progressive and chronic subtypes. J Am Acad Dermatol 1990; 22: 569–77.
10. Berti E, Tomasini D, Vermeer MH, Meijer CJ et al. Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior. Am J Pathol 1999; 155: 483–92.
11. de Wolf-Peeters C, Achten R. gammadelta T-cell lymphomas: a homogeneous entity? Histopathology 2000; 36: 294–305.
12. Berti E, Cerri A, Cavicchini S, Delia D et al. Primary cutaneous gamma/delta T-cell lymphoma presenting as disseminated pagetoid reticulosis. J Invest Dermatol 1991; 96: 718–23.
13. Toro JR, Beaty M, Sorbara L et al. gamma delta T-cell lymphoma of the skin: a clinical, microscopic, and molecular study. Arch Dermatol 2000; 136: 1024–32.
14. Toro JR, Liewehr DJ, Pabby N et al. Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma. Blood 2003; 101: 3407–12.
15. Willemze R, Beljaards RC. Spectrum of primary cutaneous CD30 (Ki-1)-positive lymphoproliferative disorders. A proposal for classification and guidelines for management and treatment. J Am Acad Dermatol 1993; 28: 973–80.
16. Bekkenk MW, Geelen FA, van Voorst Vader PC et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 2000; 95: 3653–61.
17. Diamandidou E, Colome-Grimmer M, Fayad L et al. Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis. Blood 1998; 92: 1150–9.
18. Massone C, Kodama K, Kerl H, Cerroni L. Histopathologic features of early (patch) lesions of mycosis fungoides: a morphologic study on 745 biopsy specimens from 427 patients. Am J Surg Pathol 2005; 29: 550–60.
19. Pimpinelli N, Olsen EA, Santucci M et al. Defining early mycosis fungoides. J Am Acad Dermatol 2005; 53: 1053–63.
20. Nickoloff BJ. Light-microscopic assessment of 100 patients with patch/plaque-stage mycosis fungoides. Am J Dermatopathol 1988; 10: 469–77.
21. Cerroni L, Rieger E, Hodl S, Kerl H. Clinicopathologic and immunologic features associated with transformation of mycosis fungoides to large-cell lymphoma. Am J Surg Pathol 1992; 16: 543–52.
22. Ralfkiaer E. Controversies and discussion on early diagnosis of cutaneous T-cell lymphoma. Phenotyping Dermatol Clin 1994; 12: 329–34.
23. Vermeer MH, Geelen FA, Kummer JA et al. Expression of cytotoxic proteins by neoplastic T cells in mycosis fungoides increases with progression from plaque stage to tumor stage disease. Am J Pathol 1999; 154: 1203–10.
24. Smoller BR, Santucci M, Wood GS, Whittaker SJ. Histopathology and genetics of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 2003; 17: 1277–311.
25. Karenko L, Hyytinen E, Sarna S, Ranki A. Chromosomal abnormalities in cutaneous T-cell lymphoma and in its premalignant conditions as detected by G-banding and interphase cytogenetic methods. J Invest Dermatol 1997; 108: 22–9.
26. LeBoit PE. Variants of mycosis fungoides and related cutaneous T-cell lymphomas. Semin Diagn Pathol 1991; 8: 73–81.
27. Kazakov DV, Burg G, Kempf W. Clinicopathological spectrum of mycosis fungoides. J Eur Acad Dermatol Venereol 2004; 18: 397–415.
28. Flaig MJ, Cerroni L, Schuhmann K et al. Follicular mycosis fungoides. A histopathologic analysis of nine cases. J Cutan Pathol 2001; 28: 525–30.
29. van Doorn R, Scheffer E, Willemze R. Follicular mycosis fungoides, a distinct disease entity with or without associated follicular mucinosis: a clinicopathologic and follow-up study of 51 patients. Arch Dermatol 2002; 138: 191–8.
30. Cerroni L, Fink-Puches R, Back B, Kerl H. Follicular mucinosis: a critical reappraisal of clinicopathologic features and association with mycosis fungoides and Sezary syndrome. Arch Dermatol 2002; 138: 182–9.
31. Mielke V, Wolff HH, Winzer M, Sterry W. Localized and disseminated pagetoid reticulosis. Diagnostic immunophenotypical findings. Arch Dermatol 1989; 125: 402–6.
32. Mackie RM, Turbitt ML. A case of pagetoid reticulosis bearing the T cytotoxic suppressor surface marker on the lymphoid infiltrate: further evidence that pagetoid reticulosis is not a variant of mycosis fungoides. Br J Dermatol 1984; 110: 89–94.
33. Haghighi B, Smoller BR, LeBoit PE et al. Pagetoid reticulosis (Woringer-Kolopp disease): an immunophenotypic, molecular, and clinicopathologic study. Mod Pathol 2000; 13: 502–10.
34. Drillenburg P, Bronkhorst CM, van der Wal AC et al. Expression of adhesion molecules in pagetoid reticulosis (Woringer-Kolopp disease). Br J Dermatol 1997; 136: 613–6.
35. LeBoit PE. Granulomatous slack skin. Dermatol Clin 1994; 12: 375–89.
36. Wada K, Maesawa C, Satoh T et al. A case of primary cutaneous CD30+ T-cell lymphoproliferative disorder with features of granulomatous slack skin disease. Br J Dermatol 2002; 147: 998–1002.
37. LeBoit P, Burg G, Weedon D, Sarasin A (eds.). Tumors of the skin. Lion: WHO IARC, 2005.
38. Vonderheid EC, Bernengo MG, Burg G et al. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol 2002; 46: 95–106.
39. LeBoit PE. Lymphomatoid papulosis and cutaneous CD30+ lymphoma. Am J Dermatopathol 1996; 18: 221–35.
40. Bekkenk MW, Kluin PM, Jansen PM et al. Lymphomatoid papulosis with a natural killer-cell phenotype. Br J Dermatol 2001; 145: 318–22.
41. Boulland ML, Wechsler J, Bagot M et al. Primary CD30-positive cutaneous T-cell lymphomas and lymphomatoid papulosis frequently express cytotoxic proteins. Histopathology 2000; 36: 136–44.
42. Chang SE, Park IJ, Huh J et al. CD56 expression in a case of primary cutaneous CD30+ anaplastic large cell lymphoma. Br J Dermatol 2000; 142: 766–70.
43. Drews R, Samel A, Kadin ME. Lymphomatoid papulosis and anaplastic large cell lymphomas of the skin. Semin Cutan Med Surg 2000; 19: 109–17.
44. Bijl JJ, Rieger E, van Oostveen JW et al. HOXC4, HOXC5, and HOXC6 expression in primary cutaneous lymphoid lesions. High expression of HOXC5 in anaplastic large-cell lymphomas. Am J Pathol 1997; 151: 1067–74.
45. Willemze R. Cutaneous T-cell lymphoma: epidemiology, etiology, and classification. Leuk Lymphoma 2003; 44 (Suppl. 3): S49–54.
46. Burg G, Kempf W, Cozzio A et al. WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects. J Cutan Pathol 2005; 32: 647–74.
47. Willemze R. Primary cutaneous lymphomas. Curr Opin Oncol 2000; 12: 419–25.
48. Willemze R, Meijer CJ. Rationale of a new classification for the group of primary cutaneous lymphomas. Semin Cutan Med Surg 2000; 19: 71–7.
49. Cerroni L, Zochling N, Putz B, Kerl H. Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma. J Cutan Pathol 1997; 24: 457–61.
50. Goodlad JR, Davidson MM, Hollowood K et al. Primary cutaneous B-cell lymphoma and Borrelia burgdorferi infection in patients from the Highlands of Scotland. Am J Surg Pathol 2000; 24: 1279–85.
51. Suzuki T, Matsuo K, Ito H et al. A past history of gastric ulcers and Helicobacter pylori infection increase the risk of gastric malignant lymphoma. Carcinogenesis 2006; 27: 1391–7.
52. Kazakov DV, Belousova IE, Muller B et al. Primary cutaneous plasmacytoma: a clinicopathological study of two cases with a long-term follow-up and review of the literature. J Cutan Pathol 2002; 29: 244–8.
53. Cerroni L, Volkenandt M, Rieger E et al. bcl-2 protein expression and correlation with the interchromosomal 14;18 translocation in cutaneous lymphomas and pseudolymphomas. J Invest Dermatol 1994; 102: 231–5.
54. Willemze R, Meijer CJ, Scheffer E et al. Diffuse large cell lymphomas of follicular center cell origin presenting in the skin. A clinicopathologic and immunologic study of 16 patients. Am J Pathol 1987; 126: 325–33.
55. Vermeer MH, Geelen FA, van Haselen CW et al. Primary cutaneous large B-cell lymphomas of the legs. A distinct type of cutaneous B-cell lymphoma with an intermediate prognosis. Dutch Cutaneous Lymphoma Working Group. Arch Dermatol 1996; 132: 1304–8.
56. Geelen FA, Vermeer MH, Meijer CJ et al. bcl-2 protein expression in primary cutaneous large B-cell lymphoma is site-related. J Clin Oncol 1998; 16: 2080–5.
57. Norton AJ. Classification of cutaneous lymphoma: a critical appraisal of recent proposals. Am J Dermatopathol 1999; 21: 279–87.
58. Russell-Jones R. World Health Organization classification of hematopoietic and lymphoid tissues: implications for dermatology. J Am Acad Dermatol 2003; 48: 93–102.
59. Goodlad JR, Krajewski AS, Batstone PJ et al. Primary cutaneous diffuse large B-cell lymphoma: prognostic significance of clinicopathological subtypes. Am J Surg Pathol 2003; 27: 1538–45.
60. Hallermann C, Kaune KM, Siebert R et al. Chromosomal aberration patterns differ in subtypes of primary cutaneous B cell lymphomas. J Invest Dermatol 2004; 122: 1495–502.
61. Hallermann C, Kaune KM, Gesk S et al. Molecular cytogenetic analysis of chromosomal breakpoints in the IGH, MYC, BCL6, and MALT1 gene loci in primary cutaneous B-cell lymphomas. J Invest Dermatol 2004; 123: 213–9.
62. Grange F, Bekkenk MW, Wechsler J et al. Prognostic factors in primary cutaneous large B-cell lymphomas: a European multicenter study. J Clin Oncol 2001; 19: 3602–10.
63. Heinzerling LM, Urbanek M, Funk JO et al. Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma. Cancer 2000; 89: 1835–44.

И.Э.Белоусова, Ю.А.Криволапов

Кафедра кожных и венерических болезней Военно-медицинской академии, Санкт-Петербург